Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.240
+0.050 (1.57%)
Jul 3, 2025, 4:00 PM - Market closed

Arbutus Biopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
621620419365526301
Upgrade
Market Cap Growth
44.31%47.80%15.00%-30.72%74.57%74.57%
Upgrade
Enterprise Value
513496285189556353
Upgrade
Last Close Price
3.243.272.502.333.893.55
Upgrade
PS Ratio
95.83100.4123.119.3447.8943.60
Upgrade
PB Ratio
7.846.363.952.663.112.96
Upgrade
P/TBV Ratio
7.846.363.952.663.11-
Upgrade
EV/Sales Ratio
80.1980.3215.694.8550.5951.00
Upgrade
Debt / Equity Ratio
0.070.060.080.090.110.22
Upgrade
Asset Turnover
0.050.050.110.200.060.06
Upgrade
Quick Ratio
5.878.035.714.5113.9213.06
Upgrade
Current Ratio
6.018.155.874.6014.3213.39
Upgrade
Return on Equity (ROE)
-79.02%-68.76%-59.99%-45.35%-56.19%-72.97%
Upgrade
Return on Assets (ROA)
-31.58%-33.36%-28.70%-19.76%-26.22%-29.51%
Upgrade
Return on Capital (ROIC)
-40.69%-42.21%-36.93%-23.40%-28.63%-32.60%
Upgrade
Earnings Yield
-12.34%-11.28%-17.38%-19.05%-14.49%-21.15%
Upgrade
FCF Yield
-9.51%-10.50%-20.74%-9.84%-12.99%-17.14%
Upgrade
Buyback Yield / Dilution
-11.76%-11.84%-9.95%-42.07%-40.10%-32.83%
Upgrade
Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q